Status:
COMPLETED
Apolipoprotein (APO)E Genotype, Meal Fatty Acids, Postprandial Lipaemia
Lead Sponsor:
University of Reading
Collaborating Sponsors:
Unilever R&D
Conditions:
Cardiovascular Disease
Eligibility:
MALE
18-70 years
Phase:
NA
Brief Summary
Cardiovascular disease (CVD) is the greatest cause of morbidity and mortality in the UK. Abnormalities in the concentration and/or composition of lipoproteins (the lipid carrying particles), in partic...
Eligibility Criteria
Inclusion
- Gender Male
- Age 18-70 years
- Body Mass Index (BMI) \< 32 kg/m2
- Plasma triglycerides 1-4 mmol/l
- Plasma cholesterol \< 8 mmol/l
- Glucose \< 7 mmol/l
- Haemoglobin \> 11 g/dl
- ApoE E3/E3, E3/E4
Exclusion
- Blood pressure \> 200/95 mmHg
- Had suffered a myocardial infraction or stroke in previous 2 years.
- Diabetes mellitus
- Liver disease
- Other endocrine disorders
- Unstable angina
- Familial hyperlipidaemia
- Any dietary restrictions or an a weight reducing diet
- On fatty acid supplements e.g. evening primrose oil or fish oils
- Vigorous exercise e.g. competitive athletes
- ApoE2/E2, apoE2/E3 and apoE2/E4
- Any other parameter on which the investigators felt an individual was unsuitable
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01522482
Start Date
March 1 2009
End Date
July 1 2011
Last Update
February 2 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Food and Nutritional Sciences, University of Reading
Reading, United Kingdom